| B26 | Circulating GDF15 levels are associated with aging, risk of non-AIDS comorbidities and integrated HIV DNA in ART-treated people living with HIV | E-poster | Ageing with HIV (including polypharmacy and frailty) |
| B26 | Sexual minority stress and accelerated cellular aging in treated HIV infection | E-poster | Ageing with HIV (including polypharmacy and frailty) |
| B26 | Prevalence and predictors of hypertension in aging people living with HIV attending care in Zambia | E-poster | Ageing with HIV (including polypharmacy and frailty) |
| B28 | Thirty-day hospital readmission rates among North Americans living with HIV, 2005'2015 | E-poster | Other non-communicable diseases |
| B28 | Loss of retinal nerve fiber layer and contrast sensitivity in people living with HIV with well controlled disease | E-poster | Other non-communicable diseases |
| B29 | Attained stature of HIV exposed Ugandan children by 6-18 years of life according to In-utero or peripartum antiretroviral therapy exposure type | E-poster | Other ART complications and adverse reactions |
| B30 | Opioid agonist treatment improves progression through each stage of the HIV cascade of care among people living with HIV who use opioids | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Depression, anxiety, and polysubstance use among persons with HIV: baseline findings from the Promoting Access to Care Engagement (PACE) trial | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Results from a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Anxiety and alcohol consumption in the Miami Adult Studies on HIV (MASH) cohort during the COVID-19 pandemic | E-poster | Substance abuse (including opioid use disorder) |